Payment overview · 2025
General Payments
$997.14
29 reported records · 8 companies
Healthcare provider profile · identity verified
Lynetta Lynn Stiltner, DO
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, KY · NPI 1619081502
Verified facts
What the public records show
CMS Open Payments records show Lynetta Lynn Stiltner, DO received $997.14 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $348.12 | 34.9% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $294.01 | 29.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $160.02 | 16.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.83 | 8.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.27 | 5.4% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.71 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.34 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.84 | 1.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $997.14 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $331.97 | 13 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $233.46 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $124.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $83.83 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $60.55 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.84 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 115 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 721 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 567 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 160 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 376 | 115 |
| Lisinopril | Lisinopril | 354 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 291 | 88 |
| Omeprazole | Omeprazole | 265 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 80 |
| Montelukast Sodium | Montelukast Sodium | 210 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 64 |
| Sertraline Hcl | Sertraline Hcl | 209 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 65 |
| Potassium Chloride | Potassium Chloride | 202 | 55 |
| Furosemide | Furosemide | 171 | 62 |
| Doxycycline Hyclate | Doxycycline Hyclate | 162 | 137 |
| Metformin Hcl | Metformin Hcl | 162 | 47 |
| Simvastatin | Simvastatin | 160 | 47 |
| Ezetimibe | Ezetimibe | 159 | 48 |
| Trazodone Hcl | Trazodone Hcl | 152 | 38 |
| Meloxicam | Meloxicam | 142 | 51 |
| Gabapentin | Gabapentin | 133 | 34 |
| Allopurinol | Allopurinol | 118 | 35 |
| Glipizide | Glipizide | 116 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 32 |
| Eliquis | Apixaban | 115 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 110 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 31 |
| Carvedilol | Carvedilol | 99 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 18 |
| Buspirone Hcl | Buspirone Hcl | 97 | 32 |
| Synthroid | Levothyroxine Sodium | 89 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 26 |
| Famotidine | Famotidine | 81 | 33 |
| Farxiga | Dapagliflozin Propanediol | 77 | 17 |
| Glimepiride | Glimepiride | 75 | 22 |
| Januvia | Sitagliptin Phosphate | 73 | 12 |
| Prednisone | Prednisone | 73 | 62 |
| Jardiance | Empagliflozin | 70 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 18 |
| Methylprednisolone | Methylprednisolone | 66 | 61 |
| Spironolactone | Spironolactone | 65 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Alendronate Sodium | Alendronate Sodium | 59 | 16 |
| Amoxicillin | Amoxicillin | 59 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 21 |
| Glipizide Er | Glipizide | 53 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 20 |
| Cephalexin | Cephalexin | 51 | 42 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 43 |
| Lovastatin | Lovastatin | 50 | 14 |
| Azithromycin | Azithromycin | 48 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 21 |
| Valsartan | Valsartan | 47 | 13 |
| Azelastine Hcl | Azelastine Hcl | 43 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Atenolol | Atenolol | 41 | 12 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 16 |
| Meclizine Hcl | Meclizine Hcl | 35 | 22 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 14 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 20 |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Finasteride | Finasteride | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $997.14 · 29 records | ABBVIE INC. | ABRYSVO, ACCRUFER, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, KRYSTEXXA, NURTEC ODT, PAXLOVID, PREVNAR 20, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error